Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ5E7O
|
|||
| Drug Name |
SAIT101
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 3 | [1] | |
| Company |
Archigen Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02809053) A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma (RAMO-2). U.S. National Institutes of Health. | |||
| REF 2 | Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.